CORRECTION OF INTESTINAL DYSBIOSIS IN PATIENTS WITH CHRONIC HEPATITIS C AGAINST THE BACKGROUND OF NON-ALCOHOLIC FATTY LIVER DISEASE

Purpose: to study the effectiveness of treating intestinal dysbiosis in patients with chronic hepatitis C against the background of non-alcoholic fatty liver disease using a probiotic containing Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis BB-12 and a combination of urs...

Full description

Saved in:
Bibliographic Details
Published inVisnyk problem biolohiï i medyt︠s︡yny Vol. 1; no. 3; pp. 160 - 164
Main Authors Derbak, M. A., Vorobets, V. V., Griga, V. I.
Format Journal Article
LanguageEnglish
Published Ukrainian Medical Stomatological Academy 01.11.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose: to study the effectiveness of treating intestinal dysbiosis in patients with chronic hepatitis C against the background of non-alcoholic fatty liver disease using a probiotic containing Lactobacillus acidophilus (LA5) and Bifidobacterium animalis subsp. lactis BB-12 and a combination of ursodeoxycholic acid. Object and methods. 84 patients with CHC were examined. All patients underwent a microbiological study of stool, the levels of cytokine profile indicators were determined and the psychological status and the quality of lifewere assessed. Two groups were formed depending on the prescribed treatment: 1 gr (n=40) – patients who received – LA-5 and BB-12 1 gtt. x TID and 2 g (n=44) received LA-5 and BB-12 + UDCA 500 mg qhs for 1 month. Results and their discussion. As a result of simultaneous administration of LA-5 and BB-12 and UDCA in the above-mentioned doses, in 93.2% of patients with CHC an increase in the number of bifido- and lactobacteria, Escherichia with normal activity and a decrease in the number of hemolytic microorganisms, proteus, staphylococci and yeast-like fungi, normalization of the act of defecation and the disappearance of symptoms of intestinal dysbiosis were found. In patients taking only LA-5 and BB-12, the above-mentioned positive changes were observed in 62.5%. The developed complex therapy reduces the pro-inflammatory component (the levels of fetoplacental insufficiency – α and neopterin, IL-6 decreased significantly) and activates the anti-inflammatory component of the cytokine system (IL-10 level increased significantly), improves the psychological status and the quality of life of patients. Conclusions. It was found that the additional prescription of UDCA in combination with a probiotic not only contributes to the restoration of colon microbiocenosis, but also improves the course of CHС and NAFLD, regulates the dysfunction of the cytokine link of the immune system and increases the quality of life of patients.
ISSN:2077-4214
2523-4110
DOI:10.29254/2077-4214-2022-3-166-160-164